Sunday, April 22, 2012 11:32:16 PM
Q1 $15M
Q2 $26M
Q3 $38M
Q4 $50M
Total 2012 Revenue of $129M. Company valued at 2X revenues would be $258M. If we have dilution to support the growth, i figure $2B issued. Based on these projections the real valued should be $.129 Regarding risk adjustment, I think there is a better chance of an upside buyout then a downside revenue projection. This stock will be a little undervalued for not being shareholder friendly. There is still a little lack of trust. So I think the stock goes above $.07 next week, and then continues to climb $.11 over the next three weeks.
Once they blow away my projection of Q2, this stock will climb to $.15
If my Q1 revenue projections are too high or too low; I will need to adjust my numbers after the announcement. But MusclePharm is huge! And there is no slowing it down now. I complement management for the great growth. Let's hope they can be more friendly to us investors. They are moving in the right direction!
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM